Zhejiang Tongyuan Kang Medicine

TYK Medicines is a clinical-stage biopharmaceutical company based in China, specializing in the discovery and development of innovative small molecule targeted therapies for oncology. The company's lead candidate, TY-9591, is a third-generation EGFR tyrosine kinase inhibitor currently in Phase 3 clinical trials for the treatment of non-small cell lung cancer. TYK Medicines leverages its proprietary drug discovery platform to build a robust pipeline targeting various oncogenic drivers, including CDK4/6, ROS1, and NTRK. Recently listed on the Hong Kong Stock Exchange in August 2024, the company aims to address significant unmet medical needs in the global cancer treatment landscape. The firm maintains an integrated model with research facilities in Shanghai and manufacturing capabilities in Huzhou.